Clinical Trials

Phase EARLY_PHASE1 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06637306 2026-05-14

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

15 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05673200 2026-05-13

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Phase 1 Recruiting

32 enrolled

Triple Negative Breast Neoplasms

NCT07283692 2026-05-13

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

46 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02689427 2026-05-12

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

24 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05498896 2026-05-08

BARBICAN

146 enrolled

Triple Negative Breast Neoplasms

NCT06279364 2026-05-08

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Phase 3 Recruiting

524 enrolled

Triple Negative Breast Neoplasms

NCT04771871 2026-05-07

TARMAC

42 enrolled

Phase 1 Not yet recruiting

Breast Neoplasms, Neoplastic Cells, Circulating, Triple Negative Breast Neoplasms

NCT07300475 2026-05-07

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

30 enrolled

Triple Negative Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 3 Active not recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT02488967 2026-05-06

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

782 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04331067 2026-05-06

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

15 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT06845319 2026-05-06

NeoCARD

43 enrolled

Triple Negative Breast Neoplasms

NCT06926868 2026-04-30

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

500 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02734290 2026-04-24

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

29 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03742102 2026-04-24

BEGONIA

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02957968 2026-04-21

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

46 enrolled 21 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06492759 2026-04-17

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Triple Negative Breast Neoplasms

NCT02876107 2026-04-15

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

42 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07528768 2026-04-14

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

750 enrolled

Triple Negative Breast Neoplasms

NCT02883062 2026-04-13

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

67 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06604858 2026-04-07

TELESCOPE

31 enrolled

Phase 3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05382299 2026-04-06

ASCENT-03

623 enrolled

BreastGastrointestinalOther hematologic neoplasm

Triple Negative Breast Neoplasms

NCT05768932 2026-03-27

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

260 enrolled

Carcinoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Triple Negative Breast Neoplasms

NCT05227664 2026-03-16

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

120 enrolled

Triple Negative Breast Neoplasms

NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Phase 1/2 Completed

50 enrolled 12 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT06318897 2026-03-04

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

28 enrolled

Triple Negative Breast Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

83 enrolled

Triple Negative Breast Neoplasms

NCT06976944 2026-02-23

PRELUDE

44 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

29 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05383196 2026-02-11

Onvansertib + Paclitaxel In TNBC

50 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

23 enrolled 18 charts

Phase 1 Not yet recruiting

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT03997123 2025-12-22

CAPItello-290

923 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07111832 2025-12-18

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Phase 3 Recruiting

400 enrolled

Phase 1 Active not recruiting

Triple Negative Breast Neoplasms

NCT04556773 2025-12-17

DB-08

138 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01750073 2025-11-18

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

92 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06078384 2025-11-17

ETNA

354 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02593175 2025-11-06

Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC

43 enrolled 8 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

51 enrolled

Triple Negative Breast Neoplasms

NCT03036488 2025-10-29

MK-3475-522

Phase 3 Completed

1,174 enrolled 1 FDA

Triple Negative Breast Neoplasms

NCT04443348 2025-10-14

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

120 enrolled

Triple Negative Breast Neoplasms

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

454 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01982448 2025-09-30

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

147 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT06245889 2025-09-23

NeoADAPT

30 enrolled

Phase NA Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07187674 2025-09-23

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

20 enrolled